Question 1: How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Organisation do you refer patients needing treatment to?
Question 2: How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Calquence (acalabrutinib)
c. FCR (fludarabine + cyclophosphamide + rituximab)
d. Gazyva (obinutuzumab) + chlorambucil
e. Imbruvica (ibrutinib)
f. Venclexta (venetoclax)
g. Venclexta (venetoclax) + Gazyva (obinutuzumab)
h. Venclexta (venetoclax) + rituximab
i. Zydelig (idelalisib) + rituximab
j. Any other systemic anti-cancer therapy
k. Wait and watch (monitoring only, no active treatment)
Question 3: If your Organisation does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If so, can you please provide the name of each trial along with the number of patients taking part?
